Eric Van Cutsem

173.5k total citations · 53 hit papers
1.2k papers, 95.3k citations indexed

About

Eric Van Cutsem is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Eric Van Cutsem has authored 1.2k papers receiving a total of 95.3k indexed citations (citations by other indexed papers that have themselves been cited), including 1.0k papers in Oncology, 574 papers in Pulmonary and Respiratory Medicine and 245 papers in Surgery. Recurrent topics in Eric Van Cutsem's work include Colorectal Cancer Treatments and Studies (710 papers), Gastric Cancer Management and Outcomes (384 papers) and Cancer Treatment and Pharmacology (230 papers). Eric Van Cutsem is often cited by papers focused on Colorectal Cancer Treatments and Studies (710 papers), Gastric Cancer Management and Outcomes (384 papers) and Cancer Treatment and Pharmacology (230 papers). Eric Van Cutsem collaborates with scholars based in Belgium, United States and Spain. Eric Van Cutsem's co-authors include Josep Tabernero, Salvatore Siena, David Cunningham, Marc Peeters, Yves Humblet, Philippe Rougier, Bernard Nordlinger, Atsushi Ohtsu, Chris Verslype and Yung‐Jue Bang and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Eric Van Cutsem

1.2k papers receiving 93.2k citations

Hit Papers

Trastuzumab in combination with chemotherapy vers... 1998 2026 2007 2016 2010 2004 2009 2008 2011 1000 2.0k 3.0k 4.0k 5.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    2010 5.3k citations Yung‐Jue Bang, Eric Van Cutsem et al. The Lancet profile →
  2. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
    2004 3.9k citations David Cunningham, Yves Humblet et al. profile →
  3. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
    2009 2.9k citations Eric Van Cutsem, Claus-Henning Köhne et al. profile →
  4. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
    2008 2.4k citations Marc Peeters, Eric Van Cutsem et al. Journal of Clinical Oncology profile →
  5. Everolimus for Advanced Pancreatic Neuroendocrine Tumors
    2011 2.1k citations Eric Van Cutsem et al. profile →
  6. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
    2012 2.1k citations Axel Grothey, Eric Van Cutsem et al. The Lancet profile →
  7. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
    2011 1.8k citations Éric Raymond, Jean‐Luc Raoul et al. profile →
  8. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
    2014 1.7k citations Eric Van Cutsem, G. Bodoky et al. profile →
  9. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
    2007 1.5k citations Eric Van Cutsem, Marc Peeters et al. Journal of Clinical Oncology profile →
  10. Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
    2006 1.5k citations Eric Van Cutsem, Vladimir Moiseyenko et al. Journal of Clinical Oncology profile →
  11. Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
    2019 1.5k citations Eric Van Cutsem, Teresa Macarulla et al. profile →
  12. Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
    2011 1.4k citations Eric Van Cutsem, Claus-Henning Köhne et al. Journal of Clinical Oncology profile →
  13. Gastric cancer
    2016 1.4k citations Eric Van Cutsem, Karin Haustermans et al. The Lancet profile →
  14. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
    2018 1.4k citations Sara Lonardi, Heinz‐Josef Lenz et al. Journal of Clinical Oncology profile →
  15. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
    2008 1.4k citations Philippe Rougier, Eric Van Cutsem et al. The Lancet profile →
  16. American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
    2004 1.1k citations Eric Van Cutsem et al. Journal of Clinical Oncology profile →
  17. Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
    2012 986 citations Eric Van Cutsem, Josep Tabernero et al. Journal of Clinical Oncology profile →
  18. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
    2020 975 citations Eric Van Cutsem et al. profile →
  19. Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
    2009 893 citations Sabine Tejpar, G. Bodoky et al. Journal of Clinical Oncology profile →
  20. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2014 880 citations Eric Van Cutsem, Dirk Arnold et al. Annals of Oncology profile →
  21. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial
    2013 853 citations Philippe Rougier, Eric Van Cutsem et al. profile →
  22. Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
    2011 845 citations Atsushi Ohtsu, Manish A. Shah et al. Journal of Clinical Oncology profile →
  23. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
    2012 829 citations Dirk Arnold, Richard Greil et al. profile →
  24. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
    1998 786 citations Philippe Rougier, Eric Van Cutsem et al. The Lancet profile →
  25. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
    2011 767 citations Marc Peeters, Eric Van Cutsem et al. The Lancet profile →
  26. Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
    2010 755 citations Marc Peeters, Alberto Sobrero et al. Journal of Clinical Oncology profile →
  27. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
    2007 660 citations Marc Peeters, Yves Humblet et al. Annals of Oncology profile →
  28. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
    2015 652 citations Josep Tabernero, Takayuki Yoshino et al. profile →
  29. Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer
    2004 616 citations Eric Van Cutsem, Chris Verslype et al. Journal of Clinical Oncology profile →
  30. Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer
    2015 578 citations Eric Van Cutsem, Heinz‐Josef Lenz et al. Journal of Clinical Oncology profile →
  31. Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
    2010 573 citations Salvatore Siena, Eric Van Cutsem et al. profile →
  32. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
    2017 554 citations Dirk Arnold, Marc Peeters et al. Annals of Oncology profile →
  33. Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
    2011 533 citations Josep Tabernero, Eric Van Cutsem et al. Journal of Clinical Oncology profile →
  34. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer
    2016 508 citations Fortunato Ciardiello, Josep Tabernero et al. profile →
  35. Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954
    2010 507 citations Florian Lordick, Eric Van Cutsem et al. Journal of Clinical Oncology profile →
  36. Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
    2009 504 citations Eric Van Cutsem, Yves Humblet et al. Journal of Clinical Oncology profile →
  37. Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
    2009 487 citations Catherine Lombard‐Bohas, Philippe Rougier et al. Journal of Clinical Oncology profile →
  38. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
    2021 449 citations Yelena Y. Janjigian, Sara Lonardi et al. profile →
  39. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
    2012 447 citations Carsten Bokemeyer, Eric Van Cutsem et al. profile →
  40. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
    2014 426 citations Eric Van Cutsem, Yung‐Jue Bang et al. profile →
  41. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial
    2017 414 citations Eric Van Cutsem, Michel Ducreux et al. profile →
  42. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
    2017 391 citations Manish A. Shah, Atsushi Ohtsu et al. profile →
  43. Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
    2013 379 citations Atsushi Ohtsu, Yung‐Jue Bang et al. Journal of Clinical Oncology profile →
  44. Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus
    2015 376 citations Aimery de Gramont, Philippe Rougier et al. profile →
  45. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
    2018 372 citations Eric Van Cutsem, María Alsina et al. Annals of Oncology profile →
  46. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
    2023 342 citations Kohei Shitara, Florian Lordick et al. The Lancet profile →
  47. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
    2021 331 citations Josep Tabernero, Axel Grothey et al. Journal of Clinical Oncology profile →
  48. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
    2023 213 citations Yelena Y. Janjigian, Jianming Xu et al. The Lancet profile →
  49. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
    2023 185 citations Teresa Macarulla, Eric Van Cutsem et al. The Lancet profile →
  50. Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
    2023 183 citations Julien Taı̈eb, Marwan Fakih et al. profile →
  51. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
    2022 154 citations Thierry André, Sara Lonardi et al. Annals of Oncology profile →
  52. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study
    2023 124 citations Eric Van Cutsem, Salvatore Siena et al. profile →
  53. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
    2025 34 citations Scott Kopetz, Takayuki Yoshino et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Van Cutsem Belgium 134 70.1k 36.0k 20.7k 16.2k 16.1k 1.2k 95.3k
Murray F. Brennan United States 143 38.6k 0.6× 43.3k 1.2× 31.6k 1.5× 6.8k 0.4× 5.6k 0.3× 954 81.0k
Daniel J. Sargent United States 89 37.1k 0.5× 17.9k 0.5× 12.3k 0.6× 11.6k 0.7× 7.1k 0.4× 477 57.7k
Josep Tabernero Spain 102 34.3k 0.5× 14.7k 0.4× 8.1k 0.4× 9.5k 0.6× 14.4k 0.9× 1.1k 50.8k
Jaap Verweij Netherlands 100 28.2k 0.4× 22.3k 0.6× 8.8k 0.4× 4.6k 0.3× 13.7k 0.9× 621 55.4k
Ralph H. Hruban United States 154 62.5k 0.9× 14.2k 0.4× 31.1k 1.5× 7.6k 0.5× 29.3k 1.8× 926 93.4k
Lawrence H. Schwartz United States 80 21.2k 0.3× 20.6k 0.6× 8.4k 0.4× 6.9k 0.4× 5.9k 0.4× 395 52.0k
David S. Klimstra United States 117 34.2k 0.5× 10.4k 0.3× 19.1k 0.9× 4.8k 0.3× 7.0k 0.4× 490 48.6k
Charles J. Yeo United States 115 42.3k 0.6× 17.4k 0.5× 29.0k 1.4× 3.6k 0.2× 10.8k 0.7× 579 56.1k
Richard Kaplan United Kingdom 48 22.4k 0.3× 20.2k 0.6× 7.8k 0.4× 3.9k 0.2× 7.3k 0.5× 173 46.0k
Michel Ducreux France 91 26.0k 0.4× 10.7k 0.3× 11.8k 0.6× 4.0k 0.2× 4.6k 0.3× 628 38.9k

Countries citing papers authored by Eric Van Cutsem

Since Specialization
Citations

This map shows the geographic impact of Eric Van Cutsem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Van Cutsem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Van Cutsem more than expected).

Fields of papers citing papers by Eric Van Cutsem

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Van Cutsem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Van Cutsem. The network helps show where Eric Van Cutsem may publish in the future.

Co-authorship network of co-authors of Eric Van Cutsem

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Van Cutsem. A scholar is included among the top collaborators of Eric Van Cutsem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Van Cutsem. Eric Van Cutsem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Strickler, John H., Tanios Bekaii‐Saab, Andrea Cercek, et al.. (2024). MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer. Future Oncology. 21(3). 303–311. 5 indexed citations
2.
3.
Cutsem, Eric Van, Julien Taı̈eb, Rona Yaeger, et al.. (2023). ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer. Journal of Clinical Oncology. 41(14). 2628–2637. 63 indexed citations
4.
5.
Prenen, Hans, Thierry Lesimple, Marie E. Robert, et al.. (2022). 734 A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099280, in patients with select advanced solid tumors. Regular and Young Investigator Award Abstracts. A766–A766. 2 indexed citations
6.
Hecht, J. Randolph, Sara Lonardi, Johanna C. Bendell, et al.. (2021). Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). Journal of Clinical Oncology. 39(10). 1108–1118. 78 indexed citations
7.
Cutsem, Eric Van, Hans Prenen, Kristen Spencer, et al.. (2021). 529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors. SHILAP Revista de lepidopterología. A559–A560. 11 indexed citations
8.
Chung, Hyun Cheol, Yung‐Jue Bang, Charles S. Fuchs, et al.. (2020). First-Line Pembrolizumab/Placebo Plus Trastuzumab and Chemotherapy in Her2-Positive Advanced Gastric Cancer: KEYNOTE-811. Future Oncology. 17(5). 491–501. 114 indexed citations
9.
10.
Schmoll, Hans‐Joachim, Dirk Arnold, Aimery de Gramont, et al.. (2018). MODUL—a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. Journal of Cancer Research and Clinical Oncology. 144(6). 1197–1204. 23 indexed citations
11.
Koole, Michel, Christelle Terwinghe, Kristof Baete, et al.. (2016). Dynamische und statische 68Ga-DOTATOC-PET/CT bei Patienten mit NET. Nuklearmedizin - NuclearMedicine. 55(3). 104–114. 4 indexed citations
12.
Cutsem, Eric Van, Didier Bielen, Alain Bols, et al.. (2016). Guideline on the management of rectal cancer. 1 indexed citations
13.
Cutsem, Eric Van, Heinz‐Josef Lenz, Claus-Henning Köhne, et al.. (2015). Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer. Journal of Clinical Oncology. 33(7). 692–700. 578 indexed citations breakdown →
14.
Peeters, Marc, Kelly S. Oliner, Alex Parker, et al.. (2013). Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer. Clinical Cancer Research. 19(7). 1902–1912. 185 indexed citations
15.
Vinik, Aaron I., Eric Van Cutsem, Patricia Niccoli, et al.. (2012). Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET). Pancreas. 41(2). 350–350. 4 indexed citations
16.
Cutsem, Eric Van, Sanne de Haas, Yoon‐Koo Kang, et al.. (2012). Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial. Journal of Clinical Oncology. 30(17). 2119–2127. 358 indexed citations
17.
Schmoll, Hans‐Joachim, David Cunningham, Alberto Sobrero, et al.. (2012). Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III). Journal of Clinical Oncology. 30(29). 3588–3595. 163 indexed citations
18.
Cutsem, Eric Van, Josep Tabernero, Radek Lakomý, et al.. (2012). Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. Journal of Clinical Oncology. 30(28). 3499–3506. 986 indexed citations breakdown →
19.
Bokemeyer, Carsten, et al.. (2011). EFFICACY OF CHEMOTHERAPY plus CETUXIMAB ACCORDING TO METASTATIC SITE IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER: ANALYSIS OF CRYSTAL AND OPUS STUDIES. Annals of Oncology. 22. 2 indexed citations
20.
Bang, Yung‐Jue, Eric Van Cutsem, A. Feyereislova, et al.. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet. 376(9742). 687–697. 5261 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Murray F. Brennan Breakdown of academic impact, for papers by Daniel J. Sargent Breakdown of academic impact, for papers by Josep Tabernero Breakdown of academic impact, for papers by Jaap Verweij Breakdown of academic impact, for papers by Ralph H. Hruban Breakdown of academic impact, for papers by Lawrence H. Schwartz Breakdown of academic impact, for papers by David S. Klimstra Breakdown of academic impact, for papers by Charles J. Yeo Breakdown of academic impact, for papers by Richard Kaplan Breakdown of academic impact, for papers by Michel Ducreux
Rankless by CCL
2026